Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Chordoma × Radiotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 34 Carcinoma, Non-Small-Cell Lung 21 Head and Neck Neoplasms 18 Brain Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Glioma 9 Lung Neoplasms 8 Breast Neoplasms 8 Rectal Neoplasms 7 Carcinoma, Squamous Cell 7 Astrocytoma 7 Prostatic Neoplasms 6 Neoplasms 6 Mucositis 4 Carcinoma 4 Neoplasm Metastasis 3 Esophageal Squamous Cell Carcinoma 3 Esophageal Neoplasms 3 Colorectal Neoplasms 3 Xerostomia 2 Stomatitis 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Lymphoma 2 Leukemia 2 Laryngeal Diseases 2 Gliosarcoma 2 Adenocarcinoma Of Esophagus 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1

Interventions

Imatinib Mesylate 2 spartalizumab 1 avelumab 1 Radiotherapy 1 Radiation 1 Cyclophosphamide 1 Cetuximab 1 Bacterial Load 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02383498 2024-05-20

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

NantCell, Inc.

Phase 2 Completed

24 enrolled 8 charts

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡